In October 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (^Zejula®) was approved for the maintenance treatment of relapsed ovarian cancer [1]. It can be used regardless of BRCA mutation status and received approval for the first time in Switzerland at a starting dose of 200 mg per day [1].

Special report: maintenance therapy of relapsed ovarian cancer.
Niraparib approved with individual starting doses

>>> PDF Download